Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens

TY - JOUR

T1 - Drug-target identification in Drosophila cells

T2 - combining high-throughout RNAi and small-molecule screens

AU - Perrimon, Norbert

AU - Friedman, Adam

AU - Mathey-Prevot, Bernard

AU - Eggert, Ulrike S

PY - 2007/1

Y1 - 2007/1

N2 - RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.

AB - RNA interference (RNAi) and small-molecule approaches are synergistic on multiple levels, from technology and high-throughput screen development to target identification and functional studies. Here, we describe the RNAi screening platform that we have established and made available to the community through the Drosophila RNAi Screening Center at Harvard Medical School. We then illustrate how the combination of RNAi and small-molecule HTS can lead to effective identification of targets in drug discovery.

KW - Animals

KW - Drosophila

KW - Drug Delivery Systems

KW - Drug Design

KW - Drug Evaluation, Preclinical

KW - RNA Interference

KW - RNA, Small Interfering

U2 - 10.1016/j.drudis.2006.10.006

DO - 10.1016/j.drudis.2006.10.006

M3 - Article

C2 - 17198970

SN - 1359-6446

VL - 12

SP - 28

EP - 33

JO - DRUG DISCOVERY TODAY

JF - DRUG DISCOVERY TODAY

IS - 1-2

M1 - N/A

ER -